Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gilligan

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2019
Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized TrialNeil Bayman, Wiebke Appel, Linda Ashcroft, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trialGiuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
Journal for Immunotherapy of Cancer|October 25, 2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesotheliomaKrisztian Homicsko, Panagiota Zygoura, Maxim Norkin, et al.
NPJ Precision Oncology|March 12, 2025
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancerGary Middleton, Helen L Robbins, Peter Fletcher, et al.
Nature|July 17, 2020
The National Lung Matrix Trial of personalized therapy in lung cancerGary Middleton, Peter Fletcher, Sanjay Popat, et al.
Nature|September 5, 2020
Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancerGary Middleton, Peter Fletcher, Sanjay Popat, et al.
JAMA Oncology|February 15, 2024
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical TrialPeter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, et al.
Nature Genetics|January 8, 2020
Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinomaAyesha Noorani, Xiaodun Li, Martin Goddard, et al.
JAMA Oncology|September 2, 2016
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical TrialPeter W Szlosarek, Jeremy P Steele, Luke Nolan, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2019
Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized TrialNeil Bayman, Wiebke Appel, Linda Ashcroft, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trialGiuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
Journal for Immunotherapy of Cancer|October 25, 2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesotheliomaKrisztian Homicsko, Panagiota Zygoura, Maxim Norkin, et al.
NPJ Precision Oncology|March 12, 2025
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancerGary Middleton, Helen L Robbins, Peter Fletcher, et al.
Nature|July 17, 2020
The National Lung Matrix Trial of personalized therapy in lung cancerGary Middleton, Peter Fletcher, Sanjay Popat, et al.
Nature|September 5, 2020
Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancerGary Middleton, Peter Fletcher, Sanjay Popat, et al.
JAMA Oncology|February 15, 2024
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical TrialPeter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, et al.
Nature Genetics|January 8, 2020
Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinomaAyesha Noorani, Xiaodun Li, Martin Goddard, et al.
JAMA Oncology|September 2, 2016
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical TrialPeter W Szlosarek, Jeremy P Steele, Luke Nolan, et al.
Pageof 3